Literature DB >> 35862508

Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals.

Stijn P Andeweg1, Harry Vennema1, Mirjam J Knol1, Dirk Eggink1, Irene Veldhuijzen1, Naomi Smorenburg1, Dennis Schmitz1, Florian Zwagemaker1, Arianne B van Gageldonk-Lafeber1, Susan J M Hahné1, Chantal Reusken1.   

Abstract

The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14-59 days after complete vaccination compared to ≥60 days. In contrast to vaccine-induced immunity, there was no increased risk for re-infection with Beta, Gamma or Delta variants relative to Alpha variant in individuals with infection-induced immunity.

Entities:  

Year:  2022        PMID: 35862508      PMCID: PMC9580257          DOI: 10.1126/scitranslmed.abn4338

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   19.319


  29 in total

Review 1.  A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease.

Authors:  Melissa M Higdon; Brian Wahl; Carli B Jones; Joseph G Rosen; Shaun A Truelove; Anurima Baidya; Anjalika A Nande; Parisa A ShamaeiZadeh; Karoline K Walter; Daniel R Feikin; Minal K Patel; Maria Deloria Knoll; Alison L Hill
Journal:  Open Forum Infect Dis       Date:  2022-04-18       Impact factor: 4.423

2.  SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN).

Authors:  Victoria Jane Hall; Sarah Foulkes; Andre Charlett; Ana Atti; Edward J M Monk; Ruth Simmons; Edgar Wellington; Michelle J Cole; Ayoub Saei; Blanche Oguti; Katie Munro; Sarah Wallace; Peter D Kirwan; Madhumita Shrotri; Amoolya Vusirikala; Sakib Rokadiya; Meaghan Kall; Maria Zambon; Mary Ramsay; Tim Brooks; Colin S Brown; Meera A Chand; Susan Hopkins
Journal:  Lancet       Date:  2021-04-09       Impact factor: 79.321

3.  Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.

Authors:  Anika Singanayagam; Seran Hakki; Jake Dunning; Kieran J Madon; Michael A Crone; Aleksandra Koycheva; Nieves Derqui-Fernandez; Jack L Barnett; Michael G Whitfield; Robert Varro; Andre Charlett; Rhia Kundu; Joe Fenn; Jessica Cutajar; Valerie Quinn; Emily Conibear; Wendy Barclay; Paul S Freemont; Graham P Taylor; Shazaad Ahmad; Maria Zambon; Neil M Ferguson; Ajit Lalvani
Journal:  Lancet Infect Dis       Date:  2021-10-29       Impact factor: 25.071

4.  Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021.

Authors:  Thomas Harder; Judith Koch; Sabine Vygen-Bonnet; Wiebe Külper-Schiek; Antonia Pilic; Sarah Reda; Stefan Scholz; Ole Wichmann
Journal:  Euro Surveill       Date:  2021-07

5.  Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study.

Authors:  Antonio Leidi; Flora Koegler; Roxane Dumont; Richard Dubos; María-Eugenia Zaballa; Giovanni Piumatti; Matteo Coen; Amandine Berner; Pauline Darbellay Farhoumand; Pauline Vetter; Nicolas Vuilleumier; Laurent Kaiser; Delphine Courvoisier; Andrew S Azman; Idris Guessous; Silvia Stringhini
Journal:  Clin Infect Dis       Date:  2022-03-01       Impact factor: 9.079

6.  SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Authors:  Aziz Sheikh; Jim McMenamin; Bob Taylor; Chris Robertson
Journal:  Lancet       Date:  2021-06-14       Impact factor: 79.321

7.  SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.

Authors:  Daryl Geers; Marc C Shamier; Rory D de Vries; Corine H GeurtsvanKessel; Susanne Bogers; Gerco den Hartog; Lennert Gommers; Nella N Nieuwkoop; Katharina S Schmitz; Laurine C Rijsbergen; Jolieke A T van Osch; Emma Dijkhuizen; Gaby Smits; Anouskha Comvalius; Djenolan van Mourik; Tom G Caniels; Marit J van Gils; Rogier W Sanders; Bas B Oude Munnink; Richard Molenkamp; Herbert J de Jager; Bart L Haagmans; Rik L de Swart; Marion P G Koopmans; Robert S van Binnendijk
Journal:  Sci Immunol       Date:  2021-05-25
View more
  1 in total

1.  High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020-2021.

Authors:  Timothée Dub; Anna Solastie; Lotta Hagberg; Oona Liedes; Hanna Nohynek; Anu Haveri; Camilla Virta; Saimi Vara; Mervi Lasander; Nina Ekström; Pamela Österlund; Katja Lind; Hanna Valtonen; Heidi Hemmilä; Niina Ikonen; Timo Lukkarinen; Arto A Palmu; Merit Melin
Journal:  Front Med (Lausanne)       Date:  2022-07-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.